Recent technological advances in the analysis of the human genome have opened the door to improving our primitive understanding of the gene expression patterns in cancer. For the first time, we have an overview of the complexities of tumorigenesis and metastatic progression of cancer. The examination of the phenotypic and (epi)genetic changes in cutaneous melanoma has identified several genes deemed central to the development and progression of melanoma.
Methods
A review of the recent literature was performed to determine the role of array-based high-throughput gene expression analysis in understanding the specific genes involved as well as the pathways and the comparative gene expression patterns of primary and metastatic melanoma.
Results
Most studies utilizing gene microarray analysis and other whole genome approaches reveal a wide array of genes and expression patterns in human melanoma. Furthermore, several of the same genes have been found in comparative studies, with some studies attempting correlation with clinical outcome. Several genes have been identified as potential prognostic markers of tumor progression and overall clinical outcome.
Conclusions
High-throughput gene expression analysis has had a major impact in melanoma research. Several gene expression platforms have provided insight into the gene expression patterns in melanoma. Such data will provide the foundations for the future development of prognostic markers and improved targeted therapies for patients with melanoma.
References
1.
VenterJ.C., AdamsM.D., MyersE.W.. The sequence of the human genome.Science.2001; 291(5507): 1304–1351.
2.
LanderE.S., LintonL.M., BirrenB.. Initial sequencing and analysis of the human genome.Nature.2001; 409(6822): 860–921.
3.
BirneyE., StamatoyannopoulosJ.A., DuttaA.. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project.Nature.2007; 447(7146): 799–816.
4.
LevyS., SuttonG., NgP.C.. The diploid genome sequence of an individual human.PLoS Biol.2007; 5(10): e254.
5.
JemalA., SiegelR., WardE.. Cancer statistics, 2007.CA Cancer J Clin.2007; 57(1): 43–66.
6.
HoekK., RimmD.L., WilliamsK.R.. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.Cancer Res.2004; 64(15): 5270–5282.
7.
SmithA.P., HoekK., BeckerD.. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas.Cancer Biol Ther.2005; 4(9): 1018–1029. Epub 2005 Sep 9.
8.
HaqqC., NosratiM., SudilovskyD.. The gene expression signatures of melanoma progression.Proc Natl Acad Sci U S A.2005; 102(17): 6092–6097. Epub 2005 Apr 15.
9.
TalantovD., MazumderA., YuJ.X.. Novel genes associated with malignant melanoma but not benign melanocytic lesions.Clin Cancer Res.2005; 11(20): 7234–7242.
10.
WinnepenninckxV., LazarV., MichielsS.. Gene expression profiling of primary cutaneous melanoma and clinical outcome.J Natl Cancer Inst.2006; 98(7): 472–482.
11.
JaegerJ., KoczanD., ThiesenH.J.. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdis-sected melanoma tissues.Clin Cancer Res.2007; 13(3): 806–815.
12.
HaddadF.F., StallA., MessinaJ.. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion.Ann Surg Oncol.1999; 6(2): 144–149.
13.
CascinelliN., BelliF., SantinamiM.. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience.Ann Surg Oncol.2000; 7(6): 469–474.
14.
BalchC.M., BuzaidA.C., SoongS.J.. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.J Clin Oncol.2001; 19(16): 3635–3648.
15.
BalchC.M., SoongS.J., GershenwaldJ.E.. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.J Clin Oncol.2001; 19(16): 3622–3634.
16.
EtonO., LeghaS.S., MoonT.E.. Prognostic factors for survival of patients treated systemically for disseminated melanoma.J Clin Oncol.1998; 16(3): 1103–1111.
17.
BalchC.M., BuzaidA.C., AtkinsM.B.. A new American Joint Committee on Cancer staging system for cutaneous melanoma.Cancer.2000; 88(6): 1484–1491.
SchenaM., ShalonD., DavisR.W.. Quantitative monitoring of gene expression patterns with a complementary DNA microarray.Science.1995; 270(5235): 467–470.
22.
LockhartD.J., DongH., ByrneM.C.. Expression monitoring by hybridization to high-density oligonucleotide arrays.Nat Biotechnol.1996; 14(13): 1675–1680.
23.
SchramlP., KononenJ., BubendorfL.. Tissue microarrays for gene amplification surveys in many different tumor types.Clin Cancer Res.1999; 5(8): 1966–1975.
24.
RaoJ., SeligsonD., HemstreetG.P.. Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides.Biotechniques.2002; 32(4): 924–926, 928-930, 932.
25.
DeRisiJ., PenlandL., BrownP.O.. Use of a cDNA microarray to analyse gene expression patterns in human cancer.Nat Genet.1996; 14(4): 457–460.
26.
el-DeiryW.S., TokinoT., VelculescuV.E.. WAF1, a potential mediator of p53 tumor suppression.Cell.1993; 75(4): 817–825.
27.
GravesD.T., BarnhillR., GalanopoulosT.. Expression of monocyte chemotactic protein-1 in human melanoma in vivo.Am J Pathol.1992; 140(1): 9–14.
28.
VijayasaradhiS., DoskochP.M., WolchokJ.. Melanocyte differentiation marker gp75, the brown locus protein, can be regulated independently of tyrosinase and pigmentation.J Invest Dermatol.1995; 105(1): 113–119.
29.
RyuB., KimD.S., DeLucaA.M.. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.PLoS ONE.2007; 2(7): e594.
30.
RikerA.I., EnkemannS.A., FodstadO.. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.BMC Med Genomics.2008; 1: 13. Epub Apr 28.
31.
NambiarS., MirmohammadsadeghA., DoroudiR.. Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.Arch Dermatol.2005; 141(2): 165–173.
32.
MandruzzatoS., CallegaroA., TurcatelG.. A gene expression signature associated with survival in metastatic melanoma.J Transl Med.2006; 4: 50.
33.
SeftorE.A., BrownK.M., ChinL.. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment.Cancer Res.2005; 65(22): 10164–10169.
34.
FeinbergA.P.. Phenotypic plasticity and the epigenetics of human disease.Nature.2007; 447(7143): 433–440.
35.
MuthusamyV., DuraisamyS., BradburyC.M.. Epigenetic silencing of novel tumor suppressors in malignant melanoma.Cancer Res.2006; 66(23): 11187–11193.
36.
HoonD.S., SpugnardiM., KuoC.. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.Oncogene.2004; 23(22): 4014–4022.
37.
FurutaJ., NobeyamaY., UmebayashiY.. Silencing of Peroxiredox-in 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.Cancer Res.2006; 66(12): 6080–6086.
38.
SpugnardiM., TommasiS., DammannR.. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.Cancer Res.2003; 63(7): 1639–1643.
39.
WormJ., ChristensenC., GrønbaekK.. Genetic and epigenetic alterations of the APC gene in malignant melanoma.Oncogene.2004; 23(3): 5215–5226.
GonzalgoM.L., BenderC.M., YouE.H.. Low frequency of p16/ CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.Cancer Res.1997; 57(23): 5336–5347.
42.
EstellerM.. Cancer epigenomics: DNA methylomes and histone-modification maps.Nat Rev Genet.2007; 8(4): 286–298. Epub 2007 Mar 6.
43.
LiuS., RenS., HowellP.. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.Pigment Cell Melanoma Res.2008. In press.
44.
HellebrekersD.M., MelotteV., ViréE.,. Identification of epigenetically silenced genes in tumor endothelial cells.Cancer Res.2007; 67(9): 4138–4148.
HermanJ.G., GraffJ.R., MyöhänenS.. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.Proc. Natl Acad. Sci U S A.1996; 93(18): 9821–9826.
47.
MariniA., MirmohammadsadeghA., NambiarS.. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.J Invest Dermatol.2006; 126(2): 422–431.
SigalottiL., FrattaE., CoralS.. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.J Cell. Physiol.2007; 212(2): 330–344.
50.
ZhongS., FieldsC.R., SuN.. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.Oncogene.2007; 26(18): 2621–2634. Epub 2006 Oct 9.
51.
KaramJ.A., FanJ., StanfieldJ.. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.Int J Cancer.2007; 120(8): 1795–1802.
52.
VenturelliS., ArmeanuS., PathilA.. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.Cancer.2007; 109(10): 2132–2141.
53.
AmbrosV.. The functions of animal microRNAs.Nature.2004; 431(7006): 350–355.
54.
BartelD.P.. MicroRNAs: genomics, biogenesis, mechanism, and function.Cell.2004: 116(2): 281–297.
55.
CarmellM.A., XuanZ., ZhangM.Q.. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis.Genes Dev.2002; 16(21): 2733–2742.
56.
KarubeY., TanakaH., OsadaH.. Reduced expression of Dicer associated with poor prognosis in lung cancer patients.Cancer Sci.2005; 96(2): 111–115.
57.
LeeY.S., KimH.K., ChungS.. Depletion of human microRNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation.J Biol Chem.2005; 280(17): 16635–16641. Epub 2005 Feb 18.
58.
TakamizawaJ., KonishiH., YanagisawaK.. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.Cancer Res.2004; 64(11): 3753–3756.
59.
ChanJ.A., KrichevskyA.M., KosikK.S.. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.Cancer Res.2005; 65(14): 6029–6033.
60.
CalinG.A., DumitruC.D., ShimizuM.. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.Proc Natl Acad Sci U S A.2002; 99(24): 15524–15529. Epub 2002 Nov 14.
61.
CimminoA., CalinG.A., FabbriM.. miR-15 and miR-16 induce apoptosis by targeting BCL2.Proc Natl Acad Sci U S A.2005; 102(3): 13944–13949. Epub 2005 Sep 15.
62.
IorioM.V., FerracinM., LiuC.G.. MicroRNA gene expression deregulation in human breast cancer.Cancer Res.2005; 65(16): 7065–7070.
63.
MichaelM.Z., O'ConnorS.M., van Holst PellekaanN.G.. Reduced accumulation of specific microRNAs in colorectal neoplasia.Mol Cancer Res.2003; 1(12): 882–891.
64.
XiY., NakajimaG., SchmitzJ.C.. Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer.BMC Genomics.2006; 7: 68.
65.
TazawaH., TsuchiyaN., IzumiyaM.. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.Proc Natl Acad Sci U S A.2007; 104(39): 15472–15477. Epub 2007 Sep 17.
66.
CorneyD.C., Flesken-NikitinA., GodwinA.K.. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.Cancer Res.2007; 67(18): 8433–8438. Epub 2007 Sep 6.
67.
ChangT.C., WentzelE.A., KentO.A.. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.Mol Cell.2007; 26(5): 745–752. Epub 2007 May 31.
68.
ZhangL., HuangJ., YangN.. MicroRNAs exhibit high frequency genomic alterations in human cancer.Proc Natl Acad Sci U S A.2006; 103(24): 9136–9141. Epub 2006 Jun 5.
69.
GaurA., JewellD.A., LiangY.. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines.Cancer Res.2007; 67(6): 2456–2468.
70.
BlowerP.E., VerducciJ.S., LinS.. MicroRNA expression profiles for the NCI-60 cancer cell panel.Mol Cancer Ther.2007; 6(5): 1483–1491. Epub 2007 May 4.
71.
HoodL., HeathJ.R., PhelpsM.E.. Systems biology and new technologies enable predictive and preventative medicine.Science.2004; 306(5696): 640–643.
